NCT05277493
Recruiting
Not Applicable
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
ConditionsAL Amyloidosis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- AL Amyloidosis
- Sponsor
- Peking Union Medical College Hospital
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Hematologic complete response at 3 months
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this protocol is to generate a registry of Chinese patients with AL amyloidosis treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years and older
- •newly diagnosed or refractory/relapsed AL amyloidosis
- •treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy
Exclusion Criteria
- •co-diagnosis of multiple myeloma or Waldenström's macroglobulinemia
Outcomes
Primary Outcomes
Hematologic complete response at 3 months
Time Frame: 3 months
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
Registry to Evaluate Chinese Real-World Clinical Outcomes in Patients With AF Using the WATCHMAN Left Atrial Appendage Closure TechnologyNon-valvular Atrial FibrillationNCT03917563Xijing Hospital1,050
Completed
Not Applicable
Clinical Pathway for Alzheimer's Disease in China (CPAD)Mild Cognitive ImpairmentAlzheimer's DiseaseDementiaNCT01779310Peking University1,024
Unknown
Not Applicable
A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing SpondylitisSpondylitis, AnkylosingNCT01901627Peking Union Medical College Hospital400
Recruiting
Not Applicable
A Registry of AL Amyloidosis (ReAL)AL AmyloidosisNCT04839003Fondazione IRCCS Policlinico San Matteo di Pavia5,000
Completed
Not Applicable
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research TrialsAlzheimer DiseaseCognition DisordersNCT02918539Avid Radiopharmaceuticals317